Published in
Springer, Cancer Immunology, Immunotherapy, 11(69), p. 2209-2221, 2020
DOI: 10.1007/s00262-020-02613-9
Links
Tools
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Journal article published in 2020 by
Alessio Cortellini 
,
Marcello Tiseo,
Giuseppe L. Banna,
Federico Cappuzzo,
Joachim G. J. V. Aerts,
Fausto Barbieri,
Raffaele Giusti,
Emilio Bria,
Diego Cortinovis,
Francesco Grossi,
Maria R. Migliorino,
Domenico Galetta,
Francesco Passiglia,
Daniele Santini,
Rossana Berardi
and other authors.
,
Marcello Tiseo,
Giuseppe L. Banna,
Federico Cappuzzo,
Joachim G. J. V. Aerts,
Fausto Barbieri,
Raffaele Giusti,
Emilio Bria,
Diego Cortinovis,
Francesco Grossi,
Maria R. Migliorino,
Domenico Galetta,
Francesco Passiglia,
Daniele Santini,
Rossana Berardi
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 